-+ 0.00%
-+ 0.00%
-+ 0.00%

Ganli Pharmaceutical (603087.SH): The drug under development, GLR1044 injection was approved for drug clinical trials

Zhitongcaijing·12/08/2025 11:57:11
Listen to the news

Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) issued an announcement. Recently, Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration (hereinafter referred to as the “State Drug Administration”) for the GLR1044 injection. The acceptance number is CXSL2500849, and the notification number is 2025LP03316. GLR1044 injection is a biosimilar to dupilumab® (generic name: Dupilumab, dupriumab) for the treatment of severe atopic dermatitis in adults where topical prescription drugs are poorly controlled or the use of topical prescription drugs is not recommended.